Is the neutrophil-to-lymphocyte ratio a prognostic factor in non-small cell lung cancer patients who receive adjuvant chemotherapy?

David, Smith; Raíces, Micaela; Cayol, Federico; Corvatta, Franco Alejandro; Lucas, C.F.; Dietrich, Alexander

doi:10.1053/j.seminoncol.2023.01.006

Cited by 8 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NLR, a parameter derived from the NEU divided by the LYM, is one of the most widely investigated features based on blood cell counts and serves as an indicator of systemic inflammation [36]. NLR captures the balance between the detrimental effects of increased neutrophils and the beneficial roles of adaptive immunity mediated by lymphocytes [37]. In the field of cancer research, NLR serves as an effective indicator of the dynamic balance between pro-tumor and anti-tumor responses in the body.…”

Section: Discussionmentioning

confidence: 99%

“…In the field of cancer research, NLR serves as an effective indicator of the dynamic balance between pro-tumor and anti-tumor responses in the body. Most published studies have mainly focused on the correlation between NLR and the prognosis of NSCLC [36][37][38][39][40], with little attention paid to its association with disease risk. Therese Haugdahl Nøst et al conducted a study on approximately 440,000 participants based on data from the UK Biobank, evaluating the longitudinal relationships between four systemic inflammation indicators (NLR, systemic immune-inflammation index, platelet-to-lymphocyte ratio, lymphocyte-tomonocyte ratio) and the risk of 17 cancer sites diagnosed clinically in the years preceding the study [41].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer

Ren,

Wang,

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: Recent studies have revealed that neutrophils play a crucial role in cancer progression. This study aimed to explore the diagnostic value of neutrophil-related biomarkers for non-small-cell lung cancer (NSCLC). Methods: We initially assessed the associations between classic neutrophil-related biomarkers (neutrophil-to-lymphocyte ratio (NLR), absolute neutrophil counts (NEU), absolute lymphocyte counts (LYM)) and NSCLC in 3942 cases and 6791 controls. Then, we measured 11 novel neutrophil-related biomarkers via Luminex Assays in 132 cases and 66 controls, individually matching on sex and age (±5 years), and evaluated their associations with NSCLC risk. We also developed the predictive models by sequentially adding variables of interest and assessed model improvement. Results: Interleukin-6 (IL-6) (odds ratio (OR) = 10.687, 95% confidence interval (CI): 3.875, 29.473) and Interleukin 1 Receptor Antagonist (IL-1RA) (OR = 8.113, 95% CI: 3.182, 20.689) shows strong associations with NSCLC risk after adjusting for body mass index, smoking status, NLR, and carcinoembryonic antigen. Adding the two identified biomarkers to the predictive model significantly elevated the model performance from an area under the receiver operating characteristic curve of 0.716 to 0.851 with a net reclassification improvement of 97.73%. Conclusions: IL-6 and IL-1RA were recognized as independent risk factors for NSCLC, improving the predictive performance of the model in identifying disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer

Ren,

Wang,

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Lung cancer remains the most commonly diagnosed cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 80% to 90% of all cases [ 1 , 2 ]. Lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) are the main histological subtypes of NSCLC [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

NFIC mediates m6A mRNA methylation to orchestrate transcriptional and post-transcriptional regulation to represses malignant phenotype of non-small cell lung cancer cells

Shi,

Chen,

Liu

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

Background Multiple genetic and epigenetic regulatory mechanisms are crucial in the development and tumorigenesis process. Transcriptional regulation often involves intricate relationships and networks with post-transcriptional regulatory molecules, impacting the spatial and temporal expression of genes. However, the synergistic relationship between transcription factors and N6-methyladenosine (m6A) modification in regulating gene expression, as well as their influence on the mechanisms underlying the occurrence and progression of non-small cell lung cancer (NSCLC), requires further investigation. The present study aimed to investigate the synergistic relationship between transcription factors and m6A modification on NSCLC. Methods The transcription factor NFIC and its potential genes was screened by analyzing publicly available datasets (ATAC-seq, DNase-seq, and RNA-seq). The association of NFIC and its potential target genes were validated through ChIP-qPCR and dual-luciferase reporter assays. Additionally, the roles of NFIC and its potential genes in NSCLC were detected in vitro and in vivo through silencing and overexpression assays. Results Based on multi-omics data, the transcription factor NFIC was identified as a potential tumor suppressor of NSCLC. NFIC was significantly downregulated in both NSCLC tissues and cells, and when NFIC was overexpressed, the malignant phenotype and total m6A content of NSCLC cells was suppressed, while the PI3K/AKT pathway was inactivated. Additionally, we discovered that NFIC inhibits the expression of METTL3 by directly binding to its promoter region, and METTL3 regulates the expression of KAT2A, a histone acetyltransferase, by methylating the m6A site in the 3’UTR of KAT2A mRNA in NSCLC cells. Intriguingly, NFIC was also found to negatively regulate the expression of KAT2A by directly binding to its promoter region. Conclusions Our findings demonstrated that NFIC suppresses the malignant phenotype of NSCLC cells by regulating gene expression at both the transcriptional and post-transcriptional levels. A deeper comprehension of the genetic and epigenetic regulatory mechanisms in tumorigenesis would be beneficial for the development of personalized treatment strategies.

show abstract

“…Cancer has long been reported to be associated with chronic inflammation ( 7 ). Recently, some peripheral blood-based indicators, neutrophil–lymphocyte ratio (NLR), derived NLR (dNLR), platelet–lymphocyte ratio (PLR), lymphocyte–monocyte ratio (LMR), prognostic nutritional index (PNI), the systemic immune–inflammation index (SII), and pan–immune–inflammation value (PIV) have been reported to be associated with the prognosis or stratification of several tumors, such as glioma ( 8 – 10 ), lung cancer ( 11 ), and colorectal cancer ( 12 – 14 ). However, only a few studies have reported their diagnostic value in brain tumors, particularly glioma ( 15 , 16 ).…”

Section: Introductionmentioning

confidence: 99%

Blood-based biomarkers: diagnostic value in brain tumors (focus on gliomas)

Yang,

Hu,

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

BackgroundBrain tumors, especially gliomas, are known for high lethality. It is currently understood that the correlations of tumors with coagulation and inflammation have been gradually revealed.ObjectiveThis study aimed to explore the potential value of several reported peripheral blood parameters as comprehensively as possible, with preoperative diagnosis and identification of brain tumors (focus on gliomas).MethodsPatients with central nervous system tumors (craniopharyngioma, ependymoma, spinal meningioma, acoustic neuroma, brain metastases, meningioma, and glioma) or primary trigeminal neuralgia admitted to our hospital were retrospectively analyzed. The results of the routine coagulation factor test, serum albumin test, and blood cell test in peripheral blood were recorded for each group of patients on admission. Neutrophil–lymphocyte ratio (NLR), derived NLR (dNLR), platelet–lymphocyte ratio (PLR), lymphocyte–monocyte ratio (LMR), prognostic nutritional index (PNI), the systemic immune-inflammation index (SII), pan-immune-inflammation value (PIV), and their pairings were calculated. Their ability to identify brain tumors and their correlation with glioma grade were analyzed.ResultsA total of 698 patients were included in this retrospective case–control study. Glioma patients had higher NLR, SII, and PIV but lower LMR. The NLR in the brain metastasis group was lower than that in the control, meningioma, and acoustic neuroma groups, but the SII and PIV were higher than those in the ependymoma group. Fibrinogen, white blood cell count, neutrophil count, NLR, SII, and PIV in the GBM group were higher than those in the control group. In all comparisons, NLR and NLR + dNLR showed the greatest accuracy, with areas under the curve (AUCs) of 0.7490 (0.6482–0.8498) and 0.7481 (0.6457–0.8505), respectively. PIV, dNLR + PIV, and LMR + PIV ranked second, with AUCs of 0.7200 (0.6551–0.7849), 0.7200 (0.6526–0.7874), 0.7204 (0.6530–0.7878) and 0.7206 (0.6536–0.7875), respectively.ConclusionNLR, PIV, and their combinations show high sensitivity and specificity in the diagnosis of brain tumors, especially gliomas. Overall, our results provide evidence for these convenient and reliable peripheral blood markers.

show abstract

Is the neutrophil-to-lymphocyte ratio a prognostic factor in non-small cell lung cancer patients who receive adjuvant chemotherapy?

Cited by 8 publications

References 46 publications

Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer

Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer

NFIC mediates m6A mRNA methylation to orchestrate transcriptional and post-transcriptional regulation to represses malignant phenotype of non-small cell lung cancer cells

Blood-based biomarkers: diagnostic value in brain tumors (focus on gliomas)

Contact Info

Product

Resources

About